Abstract:Background Thalidomide could relieve clinical symptoms and intestinal mucosal lesions effectively in children with refractory inflammatory bowel disease (IBD) from the pre-clinical study. This study aimed to observe the therapeutic effect of thalidomide by the established animal model of IBD model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in Sprague-Dawley (SD) rats and to investigate the possible mechanism of action. Methods A total of 82 SD rats of about 4-5 weeks were randomly divided into three groups: the control group (25 rats), TNBS-treated group (29 rats), and thalidomide treatment group (28 rats). Daily activities were recorded. At least eight rats from each group were killed on the 4th, 7th, and 14th days. Morphological and histological changes in the colon were individually assessed. Serum was collected and the levels of TNF-alpha and interleukins (IL-1 beta and IL-10) were assayed by ELISA method. The expression of colonic mucosal nuclear factor (NF)-kappa B was assayed with the immunohistochemical method. Results (1) In the control group, diarrhea and rectal bleeding recovered rapidly and no death was recorded. In the TNBS-treated group, diarrhea and rectal bleeding persisted for a longer time. The mortality rate was 10.34% during the observation period. In the thalidomide treatment group, diarrhea and rectal bleeding persisted for a significantly shorter time than the TNBS-treated group (P <0.01). The rats of this group also exhibited faster weight gain on day 7 compared with the TNBS-treated group but still lower than that of the control group. The mortality rate of the thalidomide treatment group was 3.57%. (2) Macroscopic and microscopic scores of the thalidomide-treated group were significantly lower than those of the TNBS model group on the 14th day (P <0.01). These results suggested faster and better colonic recovery in the thalidomide-treated group. (3) NF-kappa B expression in the colonic mucosa of the control group was lower than in the others, mainly distributed in the cytoplasm. A large amount of intra-nuclear and cytoplasm staining was observed (more prominently intra-nuclear) in the TNBS model group and the thalidomide treatment group. On the 7th and 14th days, intranuclear NF-kappa B-containing cells in the thalidomide treatment group were still significantly lower than those in the TNBS model group (P <0.01). (4) In the control group, the cellular inflammatory factors (TNF-alpha, IL-1 beta, and IL-10) were expressed at a low level while in the other two groups they were already expressed at a significantly higher level on day 4. On day 7 the expressions of TNF-alpha and IL-1 beta in the thalidomide treatment group were lower than in the TNBS model group. On day 14, the expressions of TNF-alpha and IL-1 beta in the thalidomide treatment group were significantly lower than in the TNBS model group (P <0.05). On day 4, the IL-10 levels of the thalidomide treatment group became significantly elevated. The levels gradually decreased but still remained at a higher level. In the TNBS model group, the IL-10 expression peaked later than in the thalidomide treatment group. Conclusions Thalidomide was effective in the management of TNBS-induced colitis in young rats. This may be due to the suppression and down-regulation of NF-kappa B and the expression of the downstream inflammatory mediators (TNF-alpha and IL-1 beta). There is also indication that the expression of the anti-inflammatory cytokine (IL-10) is concomitantly up-regulated as well.

Therapeutic potential of thalidomide and its effect in proinflammatory cytokines in adjuvant-induced arthritis rats

Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism.

Effect of thalidomide on the expression of cell adhesion molecules in fibrotic rats

Thalidomide in Rat Liver Cirrhosis: Blockade of Tumor Necrosis Factor-Alpha Via Inhibition of Degradation of an Inhibitor of Nuclear Factor-Kappab.

Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver Cirrhosis

Effects of thalidomide on the expression of NF-κB and TNF-α in experimental hepatic fibrotic rats

Observation on the Effect of Thalidomide for the Treatment of Crohn's Disease

Effects of Thalidomide on the Expression of Adhesion Molecules in Experimental Hepatic Fibrotic Rats

The Efficacy and Safety of Thalidomide in the Treatment of Refractory Crohn's Disease in Adults: a Double-Center, Double-Blind, Randomized–controlled Trial

Effects of thalidomide on adhesion molecules in rat liver fibrosis

Analysis of adverse drug reactions of thalidomide in treatment of inflammatory bowel disease

Thalidomide reduces glycerol-induced acute kidney injury by inhibition of NF-κB, NLRP3 inflammasome, COX-2 and inflammatory cytokines

Intraperitoneal Injection of Thalidomide Alleviates Early Osteoarthritis Development by Suppressing Vascular Endothelial Growth Factor Expression in Mice

Clinical study of effects of thalidomide on cytokines in patients with multiple myeloma

The Analysis of Efficacy and Safety of Thalidomide in Inflammatory Bowel Disease

Reversal Effect of Thalidomide on Established Hepatic Cirrhosis in Rats via Inhibition of Nuclear Factor-κB/Inhibitor of Nuclear Factor-κB Pathway

Protective Effects of Thalidomide on Rats with Acute Necrotizing Pancreatitis

Effects of thalidomide in experimental models of post-ERCP pancreatitis

Effects of thalidomide on the expression of MMP-13 and TIMP-1 in rat liver fibrosis

Anti-Inflammatory Effect of Thalidomide on H1N1 Influenza Virus-Induced Pulmonary Injury in Mice

Thalidomide protects mice against LPS-induced shock